A smarter way to tackle antibiotic resistance
Manchester,UK 26/08/2014 Spectromics Limited, a medical diagnostic company providing a smarter way to tackle antibiotic resistance, using its rapid point-of-prescription test, launches its new website today.
Spectromics is a company spun out of The University of Manchester by its tech transfer office (UMIP) earlier this year.
One of the major causes of antibiotic resistance is that patients are treated without the use of diagnostics to guide treatment today. To-date this has been the case because the tests required to determine resistance or susceptibility of a panel of antibiotics has taken days to perform in a laboratory, distant from the point-of- prescription. This empirical issuing of antibiotics results in giving patients antibiotics when they don’t have a bacterial infection, or an antibiotic that the infection is resistant to, both these actions allow bacteria to build further resistance.
The Spectromic solution is a 10 minute test that fits within a doctor / patient appointment and the test determines whether a bacterial infection is present, and if so which antibiotic/s will most effectively treat the particular infection.
Despite the rising incidence of antibiotic resistance, we still have a large number of antibiotics to use against infections, using these drugs effectively will reduce the escalation in resistance, and allow us to conserve last-line antibiotics.
The first test that Spectromics is developing is for urinary tract infection, the largest bacterial infection in man that accounts for 15% of all community prescribed antibiotics. The test is being designed to be simple to use by untrained staff as it’s expected to be predominantly carried out in primary care settings. However it will also have utility in institutional settings as in the US some 30% of UTI cases present at ER units due to patients feeling unwell and with a fever. By triaging patients in ER settings for UTI early the patient treatment costs associated with such infections in ER settings can be largely avoided (ER costs are 10x higher than in primary care according to a study carried out by the Henry Ford Hospital, Detroit last year).
Contact Spectromics: email email@example.com tel +44 (0)1580 891106